Literature DB >> 6446106

99mTc-hydroxymethane diphosphonate: a new bone imaging agent with a low tin content.

P A Domstad, J J Coupal, E E Kim, J S Blake, F H DeLand.   

Abstract

A prospective double-blind comparison of 99mTc-hydroxymethane diphosphonate (HMDP) and 99mTc-methylene diphosphonate (MDP) as bone-seeking agents was performed with 102 patients. Densitometry showed that both cancellous/compact bone and cancellous bone/soft-tissue ratios were greater with HMDP (p less than 0.05); compact bone/soft-tissue and bone lesion/normal bone ratios were the same with both agents. Bone delineation, soft-tissue uptake, and overall image quality were the same with both agents. The HMDP formulation contained 78% fewer stannous ions and had a longer useful life after technetium labeling than MDP.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6446106     DOI： 10.1148/radiology.136.1.6446106

Source DB:  PubMed          Journal:  Radiology        ISSN： 0033-8419            Impact factor:   11.105


  9 in total

1.  SUV measurement of normal vertebrae using SPECT/CT with Tc-99m methylene diphosphonate.

Authors:  Tomohiro Kaneta; Matsuyoshi Ogawa; Hiromitsu Daisaki; Shintaro Nawata; Keisuke Yoshida; Tomio Inoue
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-09-22

2.  Technetium-1,2-dihydroxy-1,2-bis(dihydroxyphosphinyl)ethane (99mTc-DHPE). A promising new skeletal imaging agent.

Authors:  S C Archimandritis; A K Tsolis
Journal:  Eur J Nucl Med       Date:  1987

3.  Clinical comparison of 99mTc-HMDP and 99mTc-MDP. A multicenter study.

Authors:  B Delaloye; A Delaloye-Bischof; R Dudczak; K Koppenhagen; F Mata; A Penafiel; F D Maul; J Pasquier
Journal:  Eur J Nucl Med       Date:  1985

4.  Diphosphonate bone scanning agents--current concepts.

Authors:  I Fogelman
Journal:  Eur J Nucl Med       Date:  1982

5.  Advances in drug design of radiometal-based imaging agents for bone disorders.

Authors:  Kazuma Ogawa; Hideo Saji
Journal:  Int J Mol Imaging       Date:  2011-12-15

Review 6.  Well-designed bone-seeking radiolabeled compounds for diagnosis and therapy of bone metastases.

Authors:  Kazuma Ogawa; Atsushi Ishizaki
Journal:  Biomed Res Int       Date:  2015-05-14       Impact factor: 3.411

7.  Studies on the Labeling of Ethylenediaminetetramethylene Phosphonic Acid, Methylene Diphosphonate, Sodium Pyrophosphate and Hydroxyapatite with Lutetium-177 for use in Nuclear Medicine.

Authors:  Imtiaz Ahmed Abbasi
Journal:  World J Nucl Med       Date:  2015 May-Aug

8.  Development of novel radiogallium-labeled bone imaging agents using oligo-aspartic acid peptides as carriers.

Authors:  Kazuma Ogawa; Atsushi Ishizaki; Kenichiro Takai; Yoji Kitamura; Tatsuto Kiwada; Kazuhiro Shiba; Akira Odani
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

Review 9.  Bisphosphonate conjugation for bone specific drug targeting.

Authors:  Kristen B Farrell; Alexander Karpeisky; Douglas H Thamm; Shawn Zinnen
Journal:  Bone Rep       Date:  2018-07-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.